Clinical Trials Logo
  1. Home
  2. Islet Cell Tumor
  3. NCT01374451

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET — COOPERATE-1  

Islet Cell Tumor Clinical Trial

Official title:
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study

Clinical Trial Summary

This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01374451
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date June 2011
Completion date February 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Active, not recruiting NCT00454376 - Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Phase 4
Recruiting NCT00830557 - Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00427349 - AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Phase 2
Completed NCT00434109 - Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Phase 2
Completed NCT00416767 - Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Phase 2
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3
Completed NCT00049023 - Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Phase 1
Completed NCT00006368 - Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Phase 1
Active, not recruiting NCT00730483 - Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors N/A
Terminated NCT00466856 - Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Phase 2
Completed NCT00602082 - Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00019786 - Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Phase 2
Completed NCT00017199 - PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2